First patient treated with Leqembi® (lecanemab) in Sweden
Stockholm, Sweden, September 22, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a patient in Sweden has been treated outside of a clinical study since Leqembi received EU approval in April 2025.
“I am very happy that we are now starting to help people diagnosed with early Alzheimer’s disease in Sweden as well. There is a significant unmet need for new treatment options that slow the progression of Alzheimer’s disease from its early stages